Posted by Michael Wonder on 27 Sep 2022
Merck’s Keytruda (pembrolizumab) receives four new approvals in Japan, including in high risk early stage triple negative breast cancer
27 September 2022 - Keytruda now approved for 23 uses in 13 different types of cancer in Japan.
Merck today announced that Keytruda, Merck’s anti-PD-1 therapy, received four new approvals from Japan’s MHLW.
